BELIEF is a multicentre, single-arm, phase 2 trial that investigated the safety and efficacy of erlotinib plus bevacizumab for advanced NSCLC patients with common EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.